New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:16 EDTCANFCan-Fite BioPharma submits Phase II study protocol with CF102
Can-Fite BioPharma announced that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 drug candidate has been submitted. The company plans to conduct the Phase II study in Israel, Europe and the US and will include 78 subjects with second-line treatment of advanced hepatocellular carcinoma with Child-Pugh Class B cirrhosis. The study will investigate the efficacy and safety of CF102 vs. placebo. The US Food and Drug Administration has granted Orphan Drug designation for CF102, for the treatment of hepatocellular carcinoma. According to Global Industry Analysts, the global liver cancer drug market is expected to exceed $2B by 2015.
News For CANF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
07:16 EDTCANFCan-Fite says second part of Phase II glaucoma study approved in Bulgaria
Subscribe for More Information
December 9, 2014
07:06 EDTCANFCan-Fite BioPharma to initiate development program of CF602
Can-Fite BioPharma reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies. Can-Fite reports that it received positive pre-clinical data conducted in experimental animal models demonstrating that CF602 has improved sexual dysfunction in a dose dependent manner. CF602 is a novel A3 adenosine receptor allosteric modulator, enhancing the affinity of the natural ligand adenosine to its A3 adenosine receptor.
December 5, 2014
16:16 EDTCANFEmpery Asset reports 8.43% passive stake in Can-Fite BioPharma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use